EXEL

Patrick J. Haley

Known title: EVP, CommercialCIK: 0001692954

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 4, 2026

Exelixis Shares Rise on CABOMETYX Revenue. Exelixis stock has moved higher following reports of strong revenue from its drug CABOMETYX. This performance is relevant as it demonstrates the commercial strength of the company's primary product. The FDA also expanded the label for Merck's Welireg, a competitor in the kidney cancer space, which adds context to the market environment.

this person other insiders at EXEL

Transaction History

EXEL▼ Sell$1.6M
EXEL▼ Sell$1.7M
EXEL▲ Buy$0
EXEL▼ Sell$133K
EXEL▼ Sell$2.8M
EXEL▼ Sell$1.4M
EXEL▲ Buy$0
EXEL▼ Sell$1.5M
EXEL▼ Sell$1.2M
EXEL▼ Sell$421K
EXEL▼ Sell$987K
EXEL▼ Sell$445K
EXEL▼ Sell$1.5M
EXEL▼ Sell$1.5M
EXEL▼ Sell$470K
EXEL▲ Buy$2.2M
EXEL▼ Sell$5.6M
EXEL▼ Sell$427K
EXEL▲ Buy$0
EXEL▼ Sell$388K
EXEL▲ Buy$0
EXEL▼ Sell$1.9M
EXEL▼ Sell$662K
EXEL▲ Buy$0
EXEL▼ Sell$1.0M
EXEL▼ Sell$353K
EXEL▼ Sell$762K
EXEL▼ Sell$667K
EXEL▼ Sell$514K
EXEL▲ Buy$2.4M
EXEL▼ Sell$2.5M
EXEL▼ Sell$357K
EXEL▼ Sell$93K
EXEL▼ Sell$158K
EXEL▼ Sell$188K
EXEL▼ Sell$212K
EXEL▼ Sell$1.0M
EXEL▲ Buy$0
EXEL▲ Buy$0
EXEL▼ Sell$311K
EXEL▲ Buy$815K
EXEL▼ Sell$1.2M
EXEL▼ Sell$318K
EXEL▲ Buy$0
EXEL▼ Sell$320K
EXEL▼ Sell$154K
EXEL▼ Sell$632K
EXEL▼ Sell$58K
EXEL▼ Sell$120K
EXEL▼ Sell$168K
EXEL▲ Buy$0
EXEL▼ Sell$28K
EXEL▲ Buy$105K
EXEL▼ Sell$434K
EXEL▼ Sell$120K
EXEL▼ Sell$718K
EXEL▲ Buy$248K
EXEL▲ Buy$0
EXEL▼ Sell$154K
EXEL▼ Sell$343K
EXEL▼ Sell$87K
EXEL▼ Sell$148K
EXEL▲ Buy$62K
EXEL▼ Sell$230K
EXEL▲ Buy$62K
EXEL▼ Sell$224K
EXEL▲ Buy$0
EXEL▼ Sell$610K
EXEL▼ Sell$274K
EXEL▼ Sell$15K
EXEL▲ Buy$114K
EXEL▼ Sell$1.1M
EXEL▲ Buy$0
EXEL▼ Sell$26K
EXEL▼ Sell$297K
EXEL▼ Sell$78K
EXEL▼ Sell$18K
EXEL▼ Sell$800K
EXEL▲ Buy$0
EXEL▼ Sell$112K
EXEL▲ Buy$43K
EXEL▼ Sell$509K

We use analytics to understand how market-wall is used. No personal data is sold.